In the past week, GNPX stock has gone down by -24.19%, with a monthly decline of -27.71% and a quarterly plunge of -70.79%. The volatility ratio for the week is 16.41%, and the volatility levels for the last 30 days are 14.19% for Genprex Inc The simple moving average for the past 20 days is -22.76% for GNPX’s stock, with a -73.69% simple moving average for the past 200 days.
Is It Worth Investing in Genprex Inc (NASDAQ: GNPX) Right Now?
The stock has a 36-month beta value of -0.53. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GNPX is 8.28M, and at present, short sellers hold a 4.03% of that float. On March 31, 2025, the average trading volume of GNPX was 1.99M shares.
GNPX) stock’s latest price update
The stock of Genprex Inc (NASDAQ: GNPX) has decreased by -20.73 when compared to last closing price of 0.34.Despite this, the company has seen a loss of -24.19% in its stock price over the last five trading days. prnewswire.com reported 2025-03-26 that Reqorsa® Immunogene Therapy is a Potential Therapy for Ras Inhibitor Resistant Non-Small Cell Lung Cancer AUSTIN, Texas, March 26, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, Illinois. The collaborators will present positive preclinical data from a study of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC).
Analysts’ Opinion of GNPX
Many brokerage firms have already submitted their reports for GNPX stocks, with National Securities repeating the rating for GNPX by listing it as a “Buy.” The predicted price for GNPX in the upcoming period, according to National Securities is $7 based on the research report published on January 26, 2021 of the previous year 2021.
Noble Capital Markets, on the other hand, stated in their research note that they expect to see GNPX reach a price target of $5. The rating they have provided for GNPX stocks is “Outperform” according to the report published on April 29th, 2019.
GNPX Trading at -40.67% from the 50-Day Moving Average
After a stumble in the market that brought GNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.37% of loss for the given period.
Volatility was left at 14.19%, however, over the last 30 days, the volatility rate increased by 16.41%, as shares sank -28.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -61.27% lower at present.
During the last 5 trading sessions, GNPX fell by -24.19%, which changed the moving average for the period of 200-days by -89.11% in comparison to the 20-day moving average, which settled at $0.3510. In addition, Genprex Inc saw -68.17% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GNPX
Current profitability levels for the company are sitting at:
- -985.8 for the present operating margin
- 0.64 for the gross margin
The net margin for Genprex Inc stands at -980.82. The total capital return value is set at -13.71. Equity return is now at value -325.11, with -221.01 for asset returns.
Currently, EBITDA for the company is -31.06 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 35.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
To sum up, Genprex Inc (GNPX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
